Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the
Quarterly Report on Form 10-Q of GT Biopharma, Inc. (the
“Company”),
for the quarterly period ended September 30, 2019, as filed with
the Securities and Exchange Commission on the date hereof (the
“Report”),
I, Steven Weldon, Chief Financial Officer of the Company, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge
that:
(1) The
Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934 15 U.S.C. 78m(a) or
780(d)); and
(2) The
information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
|
|
|
|
|
Date:
November 14, 2019
|
|
/s/ Steven
Weldon
|
|
|
|
|
Steven
Weldon
|
|
|
|
|
CFO,
Chief Accounting Officer, and Director
|
|
|
|
|
|
|
A signed original of this written statement required by Section 906
has been provided to GT Biopharma, Inc. and will be retained by GT
Biopharma, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.